TR201905683T4 - Aşındırıcı presbiyopi için oftalmik formülasyon ve yöntem. - Google Patents

Aşındırıcı presbiyopi için oftalmik formülasyon ve yöntem. Download PDF

Info

Publication number
TR201905683T4
TR201905683T4 TR2019/05683T TR201905683T TR201905683T4 TR 201905683 T4 TR201905683 T4 TR 201905683T4 TR 2019/05683 T TR2019/05683 T TR 2019/05683T TR 201905683 T TR201905683 T TR 201905683T TR 201905683 T4 TR201905683 T4 TR 201905683T4
Authority
TR
Turkey
Prior art keywords
presbyopia
erosive
ophthalmic formulation
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
TR2019/05683T
Other languages
English (en)
Inventor
Restrepo Luis Felipe Vejarano
Original Assignee
Restrepo Luis Felipe Vejarano
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Restrepo Luis Felipe Vejarano filed Critical Restrepo Luis Felipe Vejarano
Publication of TR201905683T4 publication Critical patent/TR201905683T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Buluş oftalmik formülasyon olup, etkili bir miktarda pilokarpin veya bunun farmasötik olarak kabul edilebilir bir tuzu, fenilefrin veya bunun farmasötik olarak kabul edilebilir bir tuzu ve nafazolin veya bunun farmasötik olarak kabul edilebilir bir tuzunu içerir.
TR2019/05683T 2012-07-19 2013-07-18 Aşındırıcı presbiyopi için oftalmik formülasyon ve yöntem. TR201905683T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/553,615 US10507245B2 (en) 2012-07-19 2012-07-19 Ophthalmic formulation and method for ameliorating presbyopia

Publications (1)

Publication Number Publication Date
TR201905683T4 true TR201905683T4 (tr) 2019-05-21

Family

ID=48917698

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/05683T TR201905683T4 (tr) 2012-07-19 2013-07-18 Aşındırıcı presbiyopi için oftalmik formülasyon ve yöntem.

Country Status (15)

Country Link
US (2) US10507245B2 (tr)
EP (1) EP2874660B1 (tr)
CN (2) CN104717981A (tr)
AR (2) AR092860A1 (tr)
BR (1) BR112015001158B1 (tr)
CO (1) CO7250451A2 (tr)
DK (1) DK2874660T3 (tr)
ES (1) ES2719250T3 (tr)
HR (1) HRP20190627T1 (tr)
MX (1) MX351230B (tr)
PL (1) PL2874660T3 (tr)
PT (1) PT2874660T (tr)
RU (1) RU2657514C2 (tr)
TR (1) TR201905683T4 (tr)
WO (1) WO2014015183A1 (tr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3049795A1 (en) 2011-09-20 2013-03-28 Juan Carlos Abad Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
ES2538551B1 (es) * 2013-12-20 2016-01-13 Eurocanarias Oftalmológica, Sl Composición Oftálmica para la corrección de la presbicia
RU2016136333A (ru) * 2014-02-11 2018-03-15 Орасис Фармасьютикалз Лтд. Фармакологическая офтальмологическая композиция, используемая в коррекции пресбиопии, и ее введение
CN104856990A (zh) * 2015-05-07 2015-08-26 武汉武药科技有限公司 去氧肾上腺素酮咯酸溶液及制备方法
US20190000808A1 (en) * 2015-07-13 2019-01-03 Allergan, Inc. Composition and methods for the treatment of blephopharoptosis
CH711969A2 (it) * 2015-12-29 2017-06-30 Pinelli Roberto Composizione per il trattamento della presbiopia.
MX2019001877A (es) 2016-08-19 2019-09-13 Orasis Pharmaceuticals Ltd Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas.
US20180318319A1 (en) 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
AU2019214557A1 (en) * 2018-02-05 2020-08-20 Cellixbio Private Limited Combination of an antimuscarinic or an anticholinergic agent and lipoic acid and uses thereof
WO2019204401A1 (en) * 2018-04-19 2019-10-24 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
EP4066830A1 (en) 2018-04-24 2022-10-05 Allergan, Inc. Use of pilocarpine hydrochloride for the treatment of ocular conditions
TW202021584A (zh) * 2018-08-21 2020-06-16 美商歐樂根公司 α2 腎上腺素受體促效劑用於改善視力之用途
US11077053B2 (en) 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
WO2020081562A1 (en) 2018-10-15 2020-04-23 Ocuphire Pharma, Inc. Methods and compositions for treatment of glaucoma and related conditions
MX2021004708A (es) 2018-10-26 2021-11-03 Ocuphire Pharma Inc Metodos y composiciones para tratamiento de presbicia, midriasis y otros trastornos oculares.
US11071724B2 (en) * 2019-05-17 2021-07-27 Ocular Science, Inc. Compositions and methods for treating presbyopia
WO2020252057A1 (en) * 2019-06-10 2020-12-17 Visus Therapeutics, Inc. Using parasympathomimetic drugs alone or, in combination with one or more alpha agonists in pseudophakic patients, to create multi-focality
MX394625B (es) * 2020-11-12 2025-03-24 Cesar Alejandro Sanchez Galeana Composicion oftalmologica sinergica en dosis de baja concentracion eficaz en la prevencion, control y erradicacion de la presbicia
CN115368310B (zh) 2021-05-18 2025-06-27 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法
EP4429652A4 (en) 2021-11-10 2025-09-10 Visus Therapeutics Inc CARBACHOL FORMULATIONS TO ENHANCE ANTI-PRESBYOPIA EFFECTS
CN116270442B (zh) * 2021-12-21 2025-07-01 浙江瑞瞳生物科技有限公司 一种用于矫正近距离视力的眼用制剂
EP4458356A4 (en) * 2021-12-28 2025-12-31 Shenyang Xingqi Pharmaceutical Co Ltd COMPOSITION AND ITS USE IN THE PREPARATION OF A MEDICINE FOR THE TREATMENT OF PRESBYOPIA
CN118236372A (zh) * 2023-03-07 2024-06-25 温州医科大学附属眼视光医院 治疗近视的药物和方法
MX2023011567A (es) * 2023-09-28 2025-04-02 Centro De Retina Medica Y Quirurgica S C Formulacion topica oftalmica de base lipidica para hacer mas eficiente la penetracion de las barreras del globo ocular de los bioactivos pilocarpina, cumarina escopoletina y patuletina presentes en el extracto de pilocarpus jaborandi y su uso en la conservacion de la salud del cristalino

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474751A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
DK335086A (da) 1985-08-05 1987-02-06 Michele Testa Kemiske sammensaetninger og farmaceutiske praeparater til topisk brug indeholdende mindst en af de kemiske sammensaetninger i en terapeutiskvirksom maengde
US4902696A (en) * 1987-10-08 1990-02-20 Hoechst-Roussel Pharmaceuticals, Inc. Synergistic intraocular pressure lowering combinations
US5192780A (en) * 1989-12-18 1993-03-09 Alcon Laboratories, Inc. Methods using antiallergics and antihistamines
US5041434A (en) * 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
ES2141775T3 (es) 1993-04-16 2000-04-01 Wakamoto Pharma Co Ltd Composicion medicinal a base de agua termicamente gelificante reversible.
US5677321A (en) 1996-02-29 1997-10-14 Synaptic Pharmaceutical Corporation 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands
IT1306135B1 (it) * 1999-04-26 2001-05-30 Farmigea Spa Composizioni oftalmiche per il trattamento delle turbe visivecaratterizzate da ridotta sensibilita' al contrasto.
US20050261641A1 (en) 2002-09-26 2005-11-24 Warchol Mark P Method for ophthalmic administration of medicament
US20060166879A1 (en) 2002-12-20 2006-07-27 Chakshu Research Inc Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
US20060172972A1 (en) 2002-12-20 2006-08-03 Chakshu Research Inc Formulation and method for administration of ophthalmologically active agents
NZ540885A (en) 2002-12-20 2009-02-28 Chakshu Res Inc Ophthalmic formulation for the prevention and treatment of ocular conditions
US20060177430A1 (en) 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US7252662B2 (en) 2004-11-02 2007-08-07 Lenticular Research Group Llc Apparatus and processes for preventing or delaying one or more symptoms of presbyopia
EP1938839B1 (en) 2006-12-18 2009-08-19 Jorge Luis Benozzi Ophthalmic compositions of parasympathetic stimulants and anti-inflammatories for use in the treatment of presbyopia
GB0724558D0 (en) 2007-12-15 2008-01-30 Sharma Anant Optical correction
TNSN08110A1 (en) 2008-03-11 2009-07-14 Rekik Raouf Dr Drug delivery to the anterior and posterior segment of the eye from drops
TWI542338B (zh) 2008-05-07 2016-07-21 壯生和壯生視覺關懷公司 用於活性劑之控制釋放的眼用裝置
WO2010125416A1 (en) 2009-04-27 2010-11-04 Raouf Rekik Drug delivery to the anterior and posterior segments of the eye
US8299079B2 (en) * 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US20100298335A1 (en) 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and Methods for Ameliorating or Reducing Presbyopia
EP2482788B1 (en) 2009-10-02 2022-12-14 Journey Medical Corporation Topical tetracycline compositions
EP2512389B1 (en) 2009-12-16 2015-09-02 Allergan, Inc. Intracameral devices for sustained delivery
US20110301555A1 (en) 2010-06-03 2011-12-08 Gonzalez-Zugasti Javier P Porous matrix drug core for lacrimal insert device
US20120003296A1 (en) 2010-07-01 2012-01-05 Shantha Totada R New methods of treating dry eye syndrome
CA3049795A1 (en) * 2011-09-20 2013-03-28 Juan Carlos Abad Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism

Also Published As

Publication number Publication date
DK2874660T3 (en) 2019-04-15
BR112015001158A2 (pt) 2017-06-27
US10507245B2 (en) 2019-12-17
MX351230B (es) 2017-10-06
US20200237916A1 (en) 2020-07-30
BR112015001158B1 (pt) 2020-12-15
ES2719250T3 (es) 2019-07-09
EP2874660A1 (en) 2015-05-27
US20140024642A1 (en) 2014-01-23
AR121843A2 (es) 2022-07-13
RU2015102531A (ru) 2016-09-10
WO2014015183A1 (en) 2014-01-23
PT2874660T (pt) 2019-05-14
EP2874660B1 (en) 2019-01-23
CN104717981A (zh) 2015-06-17
AR092860A1 (es) 2015-05-06
CO7250451A2 (es) 2015-04-30
RU2657514C2 (ru) 2018-06-14
PL2874660T3 (pl) 2019-07-31
CN113425715A (zh) 2021-09-24
HRP20190627T1 (hr) 2019-06-14
MX2015000806A (es) 2015-08-10

Similar Documents

Publication Publication Date Title
BR112015000704A2 (pt) imidazotriazinacarbonitrilas úteis como inibidores de quinase
IN2014DN10670A (tr)
EA201690713A1 (ru) Гетероциклические соединения и их применения
EA201790785A1 (ru) Производные тетрагидроизохинолина
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
EA201591420A1 (ru) Гетероарильные соединения и их применение
EA201590321A1 (ru) Дейтерированный барицитиниб
MX373678B (es) Composición farmacéutica de clorhidrato de s-cetamina.
EA033811B1 (ru) Стабильные бесконсервантные мидриатические и противовоспалительные растворы для инъекций
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
BR112014019171A8 (pt) Composições intranasais de dexdetomida e seus métodos de uso
IN2015DN00598A (tr)
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
IT1404931B1 (it) Composizioni oftalmiche per la somministrazione di principi attivi liposolubili .
BR112014028042A2 (pt) inibidores de nampt
EP2863748A4 (en) 1,2,4-triazine-6-CARBOXAMIDKINASEINHIBITOREN
MY180526A (en) Pharmaceutical composition of s-ketamine hydrochloride
WO2014160281A3 (en) Method of enhancing delivery of therapeutic compounds to the eye
BR112015001697A2 (pt) formulações de clomazona
UA114417C2 (uk) Інгібітори iap
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201500931A1 (ru) Производные пиридин-4-ила
HUE045111T2 (hu) N-(2-metoxibenzil)-4-[(metilaminokarbonil)amino]benzolszulfonamid inszekticidekkel vagy fungicidekkel képzett kombinációjának alkalmazása növénytermesztés hatásfokának növelésére
EA201690075A1 (ru) Способ лечения внутриклеточной инфекции
UY34543A (es) Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica.